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Background: Autologous bone marrow cell transplantation (BMCs-Tx) is a promising novel option for treatment of
cardiovascular disease. In this study we analyzed whether intracoronary autologous freshly isolated BMCs-Tx have
beneficial effects on cardiac function in patients with ischemic heart disease (IHD).
Results: In this prospective nonrandomized study we treated 12 patients with IHD by freshly isolated BMCs-Tx by
use of point of care system and compared them with a representative 12 control group without cell therapy.
Global ejection fraction (EF) and infarct size area were determined by left ventriculography.
Intracoronary transplantation of autologous freshly isolated BMCs led to a significant reduction of infarct size
(p< 0.001) and an increase of global EF (p = 0.003) as well as infarct wall movement velocity (p< 0.001) after
6 months follow-up compared to control group. In control group there were no significant differences of global EF,
infarct size and infarct wall movement velocity between baseline and 6 months after coronary angiography.
Furthermore, we found significant decrease in New York Heart Association (NYHA) as well as significant decrease of
B-type natriuretic peptide (BNP) level 6 months after intracoronary cell therapy (p< 0.001), whereas there were no
significant differences in control group 6 months after coronary angiography.
Conclusions: These results demonstrate that intracoronary transplantation of autologous freshly isolated BMCs by
use of point of care system is safe and may lead to improvement of cardiac function in patients with IHD.
Trial registration: Registration number: ISRCTN54510226
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Cardiac performance after myocardial infarction is com-
promised by ventricular remodelling, which represents a
major cause of late infarct-related chronic heart failure and
death [1-2]. Although conventional drug therapy may delay
remodelling, there is no basic therapeutic regimen available
for preventing or even reversing this process. By the use of
interventional therapeutics, recanalization of the occluded
infarct-related artery is possible, thereby improving or* Correspondence: dr_g_turan@hotmail.com
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distribution, and reproduction in any mediumnormalizing coronary blood flow. However, despite suffi-
cient reperfusion of infracted tissue, the viability of the
infracted myocardium cannot, or can only insufficiently,
be improved in most of these patients [3]. Cell therapy is a
promising novel option to improve vascularization or car-
diac regeneration [4]. In animal models, bone marrow-
derived stem/progenitor cell infusion improves cardiac
function and neovascularization after myocardial infarc-
tion [5-9]. Additionally, clinical trials indicate a benefical
effect of intra coronary infusion of BMCs or circulating
progenitor cells (CPCs) on myocardial function in patients
with acute myocardial infarction (AMI) [10-14]. It is un-
known whether freshly isolated BMCs transplantation
have beneficially affects postinfarction remodelling. In thisentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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influence of intracoronary freshly isolated cell therapy by
use of point of care system on cardiac function in patients
with ischemic heart disease (IHD).
Methods
Patients
In a prospective nonrandomized controlled trial, patients
between 18–80 years of age were eligible for inclusion in
this study if they had had a documented STEMI (ST-Ele-
vation myocardial infarction) on ECG at least 3 months
and had a clear-cut demarcated region of left ventricular
dysfunction with an open infarct-related coronary artery at
the time of stem cell therapy. Exclusion criteria were the
presence of acutely decompensated heart failure with a
New York Heart Association (NYHA) class of IV, infec-
tious or inflammatory disease, active bleeding, surgery or
trauma within 2 months, renal or liver dysfunction,
thrombocytopenia, or anemia, alcohol or drug depend-
ency, a history of other severe chronic diseases or cancer,
or unwillingness to participate. The local ethics committee
of University Rostock approved the study protocol. All the
participants have given their written informed consent. All
IHD patients were discharged with standard medication
consisting of acetylsalicylic acid and/or clopidogrel, an
ACE inhibitor, a ß-blocker and a statin.
Study protocol
24 IHD patients were enrolled in this prospective nonran-
domized controlled study. 12 of them underwent intracor-
onary transplantation of autologous freshly isolated BMCs
by use of point of care system whereas 12 patients served
as a control group who received only coronary angiography
and left ventriculography without any cell based therapy.
We performed in all patients of both groups before cell
transplantation a coronary angiography as well as a left ven-
triculography and presented with open infarct-related cor-
onary arteries. Patients included in the cell therapy group
underwent a bone marrow puncture and BM aspiration on
day 1 after admission. BMCs were separated. Subsequently,
after coronary angiography and left ventriculography, the
BMCs were freshly transplanted intracoronary. The primary
end point of the study was the change in global EF as well
as the size of infarcted area measured by left ventriculogra-
phy after 6 months. Secondary end point was the functional
status by NYHA classification and B-type natriuretic pep-
tide (BNP) level in peripheral blood (PB) in both groups.
All data were obtained by blinded expert readers unaware
of patient group assignment.
Preparation and administrations of BMC
A total of approximately 120 ml of bone marrow was
aspirated from the iliac crest after local anaesthesia and
mononuclear cells were isolated and identified includingCD34+ and CD133+. The bone marrow cell concentrate
suspension was isolated using the Harvest BMAC Sys-
tem (Harvest Technologies GmbH, Munich, Germany)
according to the manufactures instructions for use to
produce 20mls of concentrated cells. The concentrate
consisted of a heterogeneous cell population including
hematopoietic, mesenchymal, other progenitor cells as
well as granulocytes and platelets.
After undergoing arterial puncture, all patients
received 7500 to 10000 Units of heparin. Cell trans-
plantation was performed via the intracoronary ad-
ministration route [15] using four to six fractional
infusions parallel to balloon inflation over 2 to
4 min of 3 to 5 ml of cell suspension. All cells were
infused directly into the infarcted zone through the
infarct related artery via an angioplasty balloon cath-
eter, which was inflated at a low pressure (4 to
8 atm) and was located within the previously stented
coronary segments. This prevented back flow of cells
and produced stop flow beyond the site of balloon
inflation to facilitate high-pressure infiltration of cells
into the infarcted zone with prolonged contact time
for cellular migration. 6 months after catheter-guided
cell transplantation, all functional tests were repeated,
including coronary angiography and left ventriculogra-
phy. There were no procedural or cell-induced com-
plications and there were no side effects in any
patients.
Coronary angiography and left ventriculography
Patients in both groups underwent left heart
catheterization, left ventriculography and coronary
angiography. Cardiac function, End-diastolic volume
(LVEDV), End-systolic volume (LVESV), Stroke vol-
ume index (SVI) and infarct size were determined by
left ventriculography. Left ventriculography was per-
formed for each patients in 2 projections LAO 30/0°
and RAO 50/0°. Cardiac function was evaluated by
global EF and by auxotonic myocardial contractility
index, evaluated by the wall movement velocity of
the infarcted area. Global EF was measured with
Quantcor software (Siemens, Erlangen/Germany). To
quantify the size of infarct area we used the centre-
line method according to Sheehan [16] by plotting
five axes perpendicular to the long axis of the heart
in the main akinetic or dyskinetic segment of ven-
tricular wall. Systolic and diastolic lengths were then
measured by two blinded independent observers, and
the mean difference was divided by systolic duration
in seconds. The follow-up was 6 months after the
treatment. All hemodynamic baseline and follow-up
investigations and between the two groups were
obtained in a blinded nonrandomized order by two
independent observers/cardiologist.
Table 1 Baseline clinical characteristics of patients with
ischemic heart disease with bone marrow cells









Age 62 ± 6 60 ± 5 NS
m/f 8/4 9/3 NS
Cardiovascular Risk Factors (%)
Hypertension 70 65 NS
Hyperlipidemia 60 60 NS
Smoking 80 75 NS
Diabetes 30 30 NS
Positive family history of CAD 20 15 NS
Transmural myocardial infarction,
months before Tx
20 ± 8 24 ± 8 NS




Time from symptom onset to
first reperfusion therapy (hr)
6 ± 5 6 ± 4 NS
Primary reperfusion therapy (%) 100 100 NS
PTCA/Stent at the time of AMI 12/12 12/12 NS
Medication (%)
Aspirin 100 100 NS
Clopidogrel 100 100 NS
ACE inhibitor or AT II blocker 100 100 NS
Beta-blocker 100 100 NS
Aldosterone Antagonist 25 25 NS
Statin 100 100 NS
Laboratory parameters
CPK U/L 2010 ± 540 2145 ± 670 NS
Ischemic heart disease (IHD), Bone marrow cells transplantation (BMCs-Tx),
Coronary artery disease (CAD), Percutaneous transluminal coronary angioplasty
(PTCA), Creatine phosphokinase (CPK), Left anterior descending coronary
artery (LAD), Left circumflex artery (LCX), Right coronary artery (RCA), None
significant (NS).
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To assess any inflammatory response and myocardial re-
action after cell therapy, white blood cell count, the
serum levels of C-reactive protein (CRP) and of creatine
kinase (CK) were determined immediately before and
after treatment. Additional analysis was done directly
after transplantation and three months later: BNP level
in PB, ECG at rest, 24-h Holter ECG and echocardiog-
raphy. Procedural complications were defined as any
ventricular arrythmia, visible thrombus formation, distal
embolization, or injury of the coronary artery associated
with the cell infusion catheterization procedure.
Statistical analysis
Quantitative data are presented with mean ± SD and
qualitative data are tabulated using absolute frequencies
and/or percentages. Differences between therapy groups
for qualitative variables were tested using Fisher's-Exact-
Test due to small number of patients in therapy groups.
Within differences of quantitative variables in each ther-
apy group are compared using the Wilcoxon-Test for
depending samples, and differences between therapy
groups of quantitative variables are compared with the
Wilcoxon-Test (Mann–Whitney-Test) for independent
samples. Both of those nonparametric Wilcoxon-Tests
are prefered due to the more likely expected non-normal
distribution of the data. For all statistical tests, a result
will be seen as statistically significant, if the correspond-
ing two-sided p-value is smaller or equal to 0.05. If the
mean and the median did not differ markedly for a vari-
able, the graphical presentation of the data was be done
using the mean and SD of this variable. Statistical ana-
lysis was performed with SPSS for Windows (Version
15.0)
Results
Baseline characteristics of the patients
12 patients in the intervention group received BMCs-Tx,
whereas 12 patients in second group received no intra cor-
onary BMCs-Tx and served as a control. There were no
significant differences between the baseline characteristics
and demographics of patients between both groups. More-
over there were also no significant differences in medical
therapy at 3 and 6 months after procedure between both
groups (Table 1)
Cellular composition of point of care system from bone
marrow cells
Table 2 showed the cellular composition of bone marrow
aspirate (120 ml) and bone marrow concentrate (20 ml) as
well as viability of cells by use of point of care system. The
number of cells of total nucleated cells, CD34+, CD133+
and platelets count increased significantly post seperationin bone marrow concentrate compared to pre seperation
in bone marrow aspirate (p< 0.001).
Effect of freshly isolated BMCs transplantation
Left ventricular function, infarct size and infarct wall
movement velocity
Global EF, LVEDV, LVESV, SVI, infarct size and the wall
movement velocity of the infarcted area were measured by
left ventriculography in the first group immediately before
and 6 months after BMCs-Tx as well as in the second
group without BMCs-Tx pre- and 6 months after cardiac
catheterization. There were no significant baseline differ-
ences in global EF, LVEDV, LVESV, SVI, infarct size and
Table 2 The Cellular Composition of Bone Marrow
Aspirate and Bone Marrow Concentrate by use of point









Total nucleated cells (x106 ml) 28 ± 8 100 ± 24
CD34+ cells (x106 ml) 0.25 ± 0.08 0.93 ± 0.2
CD133+ cells (x106 ml) 0.07 ± 0.006 0.37 ± 0.04
Platelet count (x103/μl) 162 ± 21 697 ± 159
Viability of cells (%) 98 ± 1.5
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(Tables 3 and 4). 6 months after cell therapy, we observed
a significant increase of global EF and infarct wall move-
ment velocity compared to baseline. Furthermore, we
found significant decrease of infarct size after 6 months
compared to baseline (Table 3). Moreover, global EF and
wall movement velocity of the infracted area significantly
increased 6 months after cell therapy compared to control
group (Figures 1 and 2). Infarct size significantly decreased
6 months after BMCs-Tx as compared to control group
without cell therapy (Figure 3). Additionally we found a
significant increase of SVI and decrease of LVESV whereas
no significant change was observed in LVEDV 6 months
after cell therapy (Table 3). In the control group there
were no significant changes in global EF, LVEDV, LVESV,
SVI, infarct size and the wall movement velocity of the
infarcted area 6 months after coronary angiography
(Table 4).Table 3 Cardiac function, clinical parameter immediately
pre- and 6 months after bone marrrow cells







Global EF (%) 42 ± 8 54 ± 10 p = 0.001
The size of infarct
area (%)
33 ± 10 17 ± 10 p< 0.001
Infarct wall movement
velocity (cm/s)
1.70 ± 0.90 3.98 ± 0.86 p< 0.001
End-diastolic volume
(LVEDV) (ml)
128 ± 45 136 ± 50 p =NS
End-systolic volume
(LVESV) (ml)
74 ± 25 63 ± 25 p< 0.01
Stroke volume index
(SVI) (ml/m2)
30 ± 10 40 ± 8 p< 0.01
BNP (pg/ml) 169 ± 85 72 ± 21 p< 0.001
NYHA classification II-III I-II p< 0.001Functional status and clinical safety parameters
To determine the functional status we assessed NYHA
classification and BNP levels in both groups by two inde-
pendent and blinded physicians. There were no significant
differences of at baseline NYHA classification and BNP
levels between both groups. We observed significant de-
crease in NYHA classification and BNP levels 6 months
after intracoronary cell therapy, whereas there were no
significant differences in control group 6 months after
coronary angiography (Table 3 and 4). NYHA classifica-
tion and BNP levels significantly decreased 6 months after
cell therapy compared to control group (Figure 4).
ECG at rest, on exercise and 24-h Holter ECG revealed
no rhythm disturbances. There was no inflammatory re-
sponse or myocardial infarction (white blood cell count,
CRP, CK) after cell therapy. No immediate periprocedure
as well as postprocedure adverese complications and no
new electrocardiographic changes or significant elevations
in CK or troponin as well as no inflammatory response
were observed in patients with BMC-TxDiscussion
In this prospective nonrandomized controlled study we
could demonstrate improved global EF, infarct size as well
as functional status after intra coronary autologous freshly
isolated bone marrow cells transplantation in patients with
IHD.
Despite improved pharmacological therapy, congestive
heart failure remains the leading cause of cardiovascular
mortality in industrialized world [17]. The use of stem cell-Table 4 Cardiac function, clinical parameter pre- and
6 months after coronary angiography in control group









Global EF (%) 43 ± 10 44 ± 8 p=NS
The size of
infarct area (%)








132 ± 35 136 ± 48 p=NS
End-systolic volume
(LVESV) (ml)
75 ± 29 76 ± 29 p=NS
Stroke volume index
(SVI) (ml/m2)
29 ± 11 33 ± 15 p=NS
BNP (pg/ml) 155 ± 71 141 ± 69 p=NS
NYHA classification II-III II-III p =NS
Values are mean ± SD. New York Heart Association (NYHA), Global ejection
fraction (Global EF), B-type natriuretic peptide (BNP), Non significant (NS).
Figure 1 Global EF were measured by left ventriculography immediately pre and 6 months after procedure in both groups. There were
no significant baseline differences in global EF between the two groups. Global EF significantly increased 6 months after cell therapy as
compared to control group. Furthermore, no significant changes were observed in the control group at follow-up.
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the potential to salvage damaged myocardium and to pro-
mote endogenous repair of cardiac tissue, thus having the
potential for the treatment of heart failure. Experimental
studies demonstrated that intravascular or intramyocardial
administration of BMCs or CPCs may contribute to func-
tional regeneration of infarcted myocardium and enhance
neovascularization of ischaemic myocardium [5-9]. Clinical
pilot and randomized trials suggested, that the intracoronary
infusion of autologous BMCs is safe and feasible as well as
beneficially affects left ventricular contractile recovery and
infarct size in patients with AMI [10-14]. The beneficial
effects observed in most phase I/II studies were confirmed
in the so far largest douple-blind, randomized multicenterFigure 2 Infarct wall movement velocity were measured by left ventr
both groups. There were no significant baseline differences in infarct wall
velocity significantly increased 6 months after cell therapy as compared to
the control group at follow-up.REPAIR-AMI trial [14]. Only one larger study, the ASTAMI
trial [18] did not show any benefit on leftventricular func-
tional parameters. The reason for the failure of the
ASTAMI trial to show a benefit of cell therapy may have
been the different cell isolation and storage protocol,
which significantly affected the functional capacity of the
cells [19]. Likewise, it was reported, that intracoronary in-
fusion of BMCs in patients with ischemic heart disease
improve moderate left ventricular function [20-21]. In our
study, we demonstrated that the infarct size reduced,
whereas the global EF and regional infarct wall movement
velocity increased 6 months after intracoronary cell ther-
apy in patients with IHD. This observation is in line with
the data of Strauer et al [20]. and Assmus et al [21]. Iniculography immediately pre and 6 months after procedure in
movement velocity between the two groups. infarct wall movement
control group. Furthermore, no significant changes were observed in
Figure 3 Infarct size were measured by left ventriculography immediately pre and 6 months after procedure in both groups. There
were no significant baseline differences in infarct size between the two groups. There was a significant decrease of infarct size 6 months after cell
transplantation compared to control group without cell therapy. Moreover, no significant changes were observed in the control group at follow-
up.
Figure 4 NYHA classification and BNP levels in both groups. There were no significant differences of baseline NYHA classification and BNP
levels between two groups. 6 months after cell therapy there were a significant decrease of NYHA classification and BNP levels compared to
control group without cell therapy. Moreover, no significant changes were observed in the control group at follow up.
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and BNP levels 6 months after cell therapy. Because most
of the previous clinical trials involved BMCs isolated by
Ficoll [10-14], this thecnique currently viewed as the gold
standard. Cell isolation procedures are crucial for the
functional activity of the administered cellular product. In
our trial we chose to use a point of care system for the
preparation of the treating cell composition. We showed
in pilot study that freshly isolated BMCs-Tx by use a point
of care system is safe and feasible as well as may improve
the cardiac function also in patients after AMI [22]. Previ-
ous studies have demonstrated, that the mobilization and
functional activity of CD34/45+ and CD133/45+ BM-CPCs
significantly increased after intracoronary infusion of
BMCs in patients with ischemic heart disease [23-24]. We
demonstrated the same results for the first time with
intracoronary freshly isolated BMCs-Tx by use a point of
care system in patients with IHD, not Ficoll gradient sep-
aration as in other studies. Unlike many previously con-
ducted trials that employed Ficoll gradient separation as
the method of cell collection, which produces a very lim-
ited cell linage spectrum. The cellular composition of the
concentrate, which was prepared by use a point of care
system, differs from that prepared using the Ficoll method.
The Ficoll composition contains predominantly mono-
nuclear cells (lymphocytes, erythroblasts and monocytes)
and very few granulocytes. The point of care system concen-
trates entire nucleated cell population with mononuclear
cells and specific stem cell population (CD34+ and CD133
+) as well as the platelets from the marrow aspirate (Table 2).
Importantly, however, the point of care device provided ad-
vantage of significantly higher yield of isolated bone marrow
cells compared to the Ficoll protocol. Thus, if the number
of infused cells in invivo neovascularization model was
adjusted for this higher yield of bone marrow cells, the treat-
ment effect was significantly greater compared to Ficoll
BMCs, as assessed by limb perfusion measurement [25].
One obvious difference in the two compositions is the pres-
ence of significant numbers of granulocytes and platelets in
the point of care system composition. Platelets and granulo-
cytes have been shown to have a positive effect on the neo-
vascular potential of the resulting concentrate. The presence
of platelets within composition could be important because
it has been shown that these platelet-derived mediators also
potently enhance postnatal angiogenesis. Iba and colleagues
demonstrated that implantation of mononuclear cells to-
gether with platelets into ischemic limbs more effectively
augments collateral vessel formation by supplying various
angiogenic factors, in which VEGF played a key role [26]. In-
deed, Massberg and colleagues provided compel ling evi-
dence that platelets generate the critical signal that recruits
CD34+ bone marrow cells and c-Kit+Sca-1+ Lin- bone
marrow-derived progenitor cells to sites of injury [27].
Therefore, these findings strongly support the notion thatimplanted platelets play a pivotal role in stem and progenitor
recruitment and provide a rationale for the fact that point of
care system produced functional in vivo results similar to or
better than Ficoll. In our study despite higher number of
platelets we observed no immediate periprocedure as well
as postprocedure adverese complications. In addition, un-
like Ficoll isolation where cells are resuspended in a serum
free medium, point of care system is always resuspended
in the patient’s own plasma. Thus, the isolated cells are
not removed from their natural plasma microenviron-
ment, which may be help to sustain the functionality of
the cells. This has been further supported by experimental
study of Hermann et al., who showed that the point of
care system composition to be significantly more bioactive
than the Ficoll composition. Intriguingly, however, due to
the greater yield of cells generated by use a point of care
system, the cellular product isolated from a given bone
marrow aspirate by use a point of care device may actually
translate into even greater therapeutic effects. Addition-
ally, practical aspects may also deserve consideration. Im-
portantly, a major limitation of the Ficoll isolation
procedure for clinical applications is that it is strongly in-
vestigator dependant, immensely time consuming and
requires a good manufacturing practice (GMP) facility. In
this study we were able to demonstrate that such complex
methods are not necessary to achieve established results.
As the concentration process by use of point of care sys-
tem, everything can be accomplished in one session with-
out adding excessive time to the overall procedure
circumventing the previously mentioned disadvantages of
the Ficoll isolation process. The point of care device pro-
vides a much shorter turnaround time. Therefore, this de-
vice represents a cost-effective and time-efficient stand-
alone technique for the isolation of autologous bone mar-
row cells suitable for cell therapy regimens in the rapidly
growing field of regenerative medicine.
Several hypotheses have been proposed about, how intra-
coronary cell therapy improves myocardial function. I) Ex-
perimental studies addressing the capacity of transplanted
bone marrow-derived stem cells to differentiate into the
cardiomyogenic lineage yielded conflicting results. Recent
well-conducted studies suggest that the BMCs do not trans-
differentiate into cardiomyocytes but adopt mature hemato-
poeitic characteristics. In contrast to embryonic stem cells,
most adult stem or progenitor cells do not spontaneously
differentiate into cardiomyocytes but rather require an ad-
equate stimulus to do so. II) Another proposed mechanism
is that cell therapy may increase angiogenesis and improve
blood supply to ischemic regions, potentially aiding in the
revascularization of hibernating myocardium and inhibiting
cardiomyocyte apoptosis. Additionally or alternatively, the
local microenvironment plays an important role to induce
cell fate changes by physical cell-to-cell interaction or by
providing paracrine factors promoting tissue repair [28-30].
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of ischemic disease. However, cell therapy is in its early
stages, and various questions remain. BMCs are best
characterized and have been used in the majority of clin-
ical trials performed to date. BMCs contains a complex
assortment of progenitor cells, including hematopoietic
stem cells (HSCs), mesenchymal stem cells (MSCs) or
stromal cells and multipotential adult progenitor cells
(MAPCs) [31]. Additionally, The presence of immature
circulating cells in the peripheral blood has been advo-
cated as a marker of an organism`s regenerative capacity
[32].
The primary limitation of this study is the only use of
left ventriculography for cardiac function without the
additionally measurement of cardiac imaging. However
the same assessments was used in several studies [10,
14, 15, 20, 21]. Moreover, for better understanding we
added left ventricular volume data in our study. Sec-
ondly the placebo effect on improvement of NYHA clas-
sification in cell therapy group can not be excluded due
to the obvious. On the other hand this result was con-
firmed indirectly by decrease of BNP values in PB and
improvement of global EF. Therefore, a randomized pla-
cebo-controlled study will be needed to validate the
hypothesis.Conclusions
In the present study we could demonstrate that intracor-
onary transplantation of autologous freshly isolated
BMCs by point of care system improved global EF and
reduced infarct size significantly in patients with IHD
after 6 months. Moreover, we observed a significant de-
crease of NYHA-classification and BNP levels even
6 months after cell transplantation. This interesting ob-
servation could be implemented in future large-scale
randomized studies.
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